Aptose Biosciences Inc.

OTCPK:APTO.F Stock Report

Market Cap: US$3.7m

Aptose Biosciences Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Aptose Biosciences.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth24.7%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Seeking Alpha • Aug 01

Aptose Biosciences Q2 2022 Earnings Preview

Aptose Biosciences (NASDAQ:APTO) is scheduled to announce Q2 earnings results on Monday, August 1st, after market close. The consensus EPS Estimate is -$0.13 and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 6 upward revisions and 0 downward.
Seeking Alpha • Jul 19

Aptose Biosciences Continues To Drift Without Thesis-Changing Data

Aptose has made some progress in the clinic this year, including additional complete responses for lead program HM43239 and a new formulation of luxeptinib. Expansion studies of '239 in 2023 could pave the way toward registration studies, and dose escalation studies of the new luxeptinib formulation could begin in early 2023. There is a sizable market opportunity for drugs to address patients with hematological cancers who've progressed on other therapies, but the odds and timelines are long. I believe fair value for Aptose is around $4 today, but upside is tied to future positive clinical developments and there's not much room for stumbles or setbacks. It wouldn't be fair to say that there's been no clinical progress at Aptose Biosciences (APTO) since my last update, but there certainly hasn't been enough to really sway investor sentiment, particularly in light of a more risk-averse biotech market. Aptose has two credible hematological oncology products in the pipeline, but there is a still lot of de-risking needed for both programs. I do believe that the market is still heavily discounting the odds of clinical success here, but given the history of oncology drug development, and Aptose's own shaky clinical progress, that's not exactly unfair. I can still see a path toward a substantially higher fair value, but the reality is that investors are likely going to need to wait a year or more for sentiment-moving data. '239 Is Worth Further Exploration From five complete responses and one partial response back at the December 2021 ASH update, Aptose has seen two more complete responses in its HM43239 (or '239) program in relapsed or refractory AML, bringing the total to seven complete responses and one partial response among a 80mg, 120mg, and 160mg dosing group that has treated at least 41 patients as off the last cut-off (early June, ahead of the EHA meeting). Thus far the drug has shown encouraging safety/tolerability, with only one dose-limiting toxicity reported so far (muscle weakness in a patient getting a 200mg dose). While the response rates aren't eye-popping at this point, it's worth remembering that these are not the healthiest patients, as they've already seen drug progression after prior treatments. Based on the early clinical results, management is moving forward with further dose exploration at 80mg, 120mg, and 160mg (the 80mg segment has been completed, with the 120mg and 160mg cohorts about half-complete as of early June) and then two expansion studies. One expansion study will use 120mg (with 80mg and 160mg as bracketing dosages) of '293 as a single-agent therapy in FLT-3 mutated and unmutated AML, while the other will be a combination study with venetoclax (Venclexta, marketed by AbbVie (ABBV) and Roche (RHHBY)). The single-agent study should start later this year, with the combo study slated for the first half of 2023. Should the results of these studies merit it, registrational studies would then start - presumably in 2024 for the single-agent study. It's worth remembering that '293 is targeting the challenging r/r AML market. While there are solid treatment options available as front-line therapies, some patients cannot tolerate them, some do not respond, and others ultimately see their disease mutate around the treatment and become non-responsive/relapsing. Keep this in mind when comparing response rates to other drugs in the space (make sure it's an "apples to apples" comparison). Another Chance For Luxeptinib Aptose's prior lead drug, luxeptinib, still factors significantly into the company's clinical plans today. While the drug showed exciting pre-clinical attributes, clinical results today have not matched that potential. It would seem that the pharmacokinetics of the drug are at least partly to blame, and the company is hoping that a reformulated version of the drug (known as "G3") can lead to patients getting consistent therapeutic doses that produce clinical results. Clinical trial work is underway now, with patients getting G3 at 50mg, 100mg, and 200mg doses and the 50mg dose of G3 demonstrating 200x the exposure level of a 150mg dose of G1. Assuming that the pharmacokinetics and pharmacodynamics (PK and PD) studies merit further development, Aptose should be able to start dose escalation studies of the new formulation in the first half of 2023 in patients with r/r B-cell or r/r AML disease.
Seeking Alpha • Feb 02

Aptose Deep In The Doghouse Due To Lack Of Pipeline Progress

A lack of progress in the clinic, including another disappointing ASH meeting, has led investors to bail out of this risky early-stage biotech. A new formulation of luxeptinib, and potentially greater exposure to the drug, may finally unlock the potential of this once-promising drug, but it's a "show me" story. Recently-acquired '239 looks like an interesting asset for AML, with promising Phase 1 response rates, but it's still early in the development cycle. Between '239 and luxeptinib there is still potential in Aptose's pipeline, but it will take real evidence of clinical efficacy to rebuild sentiment.

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Aptose Biosciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

OTCPK:APTO.F - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2025N/A-25-22-22N/A
9/30/2025N/A-19-24-24N/A
6/30/2025N/A-21-27-27N/A
3/31/2025N/A-21-27-27N/A
12/31/2024N/A-25-36-36N/A
9/30/2024N/A-36-37-37N/A
6/30/2024N/A-40-37-37N/A
3/31/2024N/A-47-45-45N/A
12/31/2023N/A-51-45-45N/A
9/30/2023N/A-49-44-44N/A
6/30/2023N/A-48-40-40N/A
3/31/2023N/A-44-34-34N/A
12/31/2022N/A-42-32-32N/A
9/30/2022N/A-56-40-40N/A
6/30/2022N/A-58-41-41N/A
3/31/2022N/A-61-43-43N/A
12/31/2021N/A-65-44-43N/A
9/30/2021N/A-56-38-38N/A
6/30/2021N/A-58-38-38N/A
3/31/2021N/A-60-36-36N/A
12/31/2020N/A-55-34-34N/A
9/30/2020N/A-48-30-30N/A
6/30/2020N/A-42-27-27N/A
3/31/2020N/A-32-25-25N/A
12/31/2019N/A-26-22-22N/A
9/30/2019N/A-25N/A-21N/A
6/30/2019N/A-24N/A-20N/A
3/31/2019N/A-28N/A-24N/A
12/31/2018N/A-29N/A-23N/A
9/30/2018N/A-26N/A-21N/A
6/30/2018N/A-23N/A-18N/A
3/31/2018N/A-15N/A-12N/A
12/31/2017N/A-12N/A-10N/A
9/30/2017N/A-11N/A-10N/A
6/30/2017N/A-12N/A-11N/A
3/31/2017N/A-14N/A-12N/A
12/31/2016N/A-14N/A-12N/A
9/30/2016N/A-15N/A-12N/A
6/30/2016N/A-14N/A-12N/A
3/31/2016N/A-12N/A-12N/A
1/1/2016N/A-12N/A-10N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if APTO.F's forecast earnings growth is above the savings rate (3.5%).

Earnings vs Market: Insufficient data to determine if APTO.F's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if APTO.F's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if APTO.F's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if APTO.F's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if APTO.F's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/07 10:53
End of Day Share Price 2026/05/07 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aptose Biosciences Inc. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthew VeneziaAlliance Global Partners
Dylan DupuisB. Riley Securities, Inc.
John NewmanCanaccord Genuity